10.42

6.46% -0.72

Solid Biosciences Inc (SLDB)

Overview News Price History Option Chain Financials Why SLDB Down? Discussions Forecast Stock Split

Solid Biosciences Inc stock is traded at $10.42, with a volume of 1.47M. It is down -6.46% in the last 24 hours and up +57.64% over the past month. Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Previous Close:

$11.14

Open:

$11.11

24h Volume:

1.47M

Relative Volume:

0.91

Market Cap:

$1.03B

Revenue:

$14.79M

Net Income/Loss:

$-191.78M

P/E Ratio:

-5.3532

EPS:

-1.9465

Net Cash Flow:

$-172.86M

1W Performance:

-3.87%

1M Performance:

+57.64%

6M Performance:

+96.98%

1Y Performance:

+92.25%

1-Day Range:

$9.91

$11.11

1-Week Range:

$9.91

$11.45

52-Week Range:

$3.79

$11.45

Solid Biosciences Inc Stock (SLDB) Company Profile

Name

Solid Biosciences Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

617-337-4680

Address

500 RUTHERFORD AVENUE, CHARLESTOWN, MA

Employee

121

Twitter

@SolidBioDMD

Next Earnings Date

2026-08-11

Latest SEC Filings

SLDB's Discussions on Twitter

Compare SLDB vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLDB Solid Biosciences Inc	10.42	1.03B	14.79M	-191.78M	-172.86M	-1.9465
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-20-26	Initiated	Guggenheim	Buy
Dec-04-25	Initiated	Needham	Buy
Jun-26-25	Initiated	Citigroup	Buy
Jan-08-25	Initiated	Truist	Buy
Dec-13-24	Initiated	Wedbush	Outperform
Dec-10-24	Initiated	JMP Securities	Mkt Outperform
Jul-15-24	Upgrade	JP Morgan	Neutral → Overweight
Jun-24-24	Upgrade	Leerink Partners	Market Perform → Outperform
May-31-24	Resumed	Piper Sandler	Overweight
Mar-28-24	Initiated	William Blair	Outperform
Mar-15-24	Initiated	Citigroup	Buy
Mar-14-24	Upgrade	Piper Sandler	Neutral → Overweight
Dec-08-23	Initiated	H.C. Wainwright	Buy
Jul-12-21	Initiated	Piper Sandler	Neutral
May-27-21	Initiated	Jefferies	Buy
Mar-16-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-09-21	Initiated	Barclays	Overweight
Jan-08-21	Upgrade	Credit Suisse	Underperform → Neutral
Jul-28-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-07-20	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-19	Initiated	Evercore ISI	Outperform
Aug-29-19	Downgrade	Citigroup	Neutral → Sell
Aug-19-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Aug-16-19	Upgrade	Chardan Capital Markets	Neutral → Buy
May-14-19	Downgrade	Credit Suisse	Neutral → Underperform
May-14-19	Downgrade	Goldman	Neutral → Sell
Feb-08-19	Upgrade	Citigroup	Sell → Neutral
Feb-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-18	Initiated	Citigroup	Sell
Sep-06-18	Initiated	Credit Suisse	Neutral

View All

Solid Biosciences Inc Stock (SLDB) Latest News

Jul 10, 2026

How Investors May Respond To Solid Biosciences (SLDB) Joining Multiple Russell Growth Indices - simplywall.st

Jul 10, 2026

Jul 09, 2026